The objective of this study was to assess the incidence, timing and identify pharmacogenetic, efavirenz (EFV) pharmacokinetic and biochemical predictors of EFV-based antiretroviral therapy (ART) drug-induced liver injury (DILI). ART-naïve HIV patients (n ¼ 285) were prospectively enrolled. Pretreatment laboratory evaluations included hepatitis B surface antigen and C antibody, CD4 count and viral load. Liver tests were done at baseline, 1st, 2nd, 4th, 8th, 12th, 24th and 48th weeks during ART. Plasma EFV and 8-hydroxyefvairenz concentration was determined at week 4 using liquid chromatography-mass spectrometry. CYP2B6, CYP3A5, ABCB1 3435C/T and UGT2B7*2 genotyping was done using Taqman genotyping assay. Data were analyzed using survival analysis and Cox proportional hazards model. The incidence of DILI was 15.7% or 27.9 per 100 person-years and that of severe injury was 3.4% or 6.13 per 100 person-years. The median time for the development of DILI and severe injury was 2 and 4 weeks after initiation of ART, respectively. There was significant association of DILI with lower baseline platelet, albumin, log plasma viral load and CD4 count (P ¼ 0.031, 0.037, 0.06 and 0.019, respectively). Elevated baseline alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, plasma EFV level and CYP2B6*6 were good predictors for the development of DILI (P ¼ 0.03, 0.01, 0.016, 0.017 and 0.04, respectively). We report for the first time CYP2B6*6 as a putative genetic marker and high plasma EFV concentration as intermediate biomarker for vulnerability to EFV-induced liver injury in HIV patients. CYP2B6 genotyping and/or regular monitoring of EFV and lever enzymes level during early therapy is advised for early diagnosis and management of DILI.
Introduction
Antiretroviral drug-induced liver injury (DILI), a common and serious adverse drug reaction, is one of the most challenging clinical problems, common cause of hospitalization and life-threatening events in HIV patients. 1, 2 Previous studies have shown that up to 30% of patients getting antiretroviral therapy (ART) developed liver injury, and all marketed non-nucleoside reverse transcriptase inhibitors and protease inhibitors were incriminated for this. [3] [4] [5] [6] [7] Identification of the associated risks and predictors is imperative to prevent unnecessary death from ART-induced liver injury. If not detected early and managed properly, it may lead to poor adherence, which might result in serious consequences both for the patient and for the community at large. There are different classes of antiretroviral drugs with different metabolic profiles in the liver. Accordingly predictors and incidence of treatment associated with liver injury may vary with the antiretroviral drugs. Use of nonnucleoside reverse transcriptase inhibitors, including nevirapine and efavirenz (EFV), has been associated with severe hepatic injury. 8 Nevirapine has a greater risk in causing liver injury when compared with EFV, with an incidence rate reaching up to 28.6% and 13.6%, respectively. 8, 9 EFV is metabolized by liver enzymes, mainly by CYP2B6 and to a less extent by CYP3A4/5.
10 UGT2B7 is also involved in direct EFV and 8-hydroxyefavirenz glucuronidation. 11 Although whether EFV is a substrate for P-glycoprotein remains controversial, recent studies reported influence of ABCB1 genetic variations on EFV kinetics. 12, 13 Ethnicity and pharmacogenetic variations are well documented to influence between-patient variability of EFV pharmacokinetics. 10, 12, [14] [15] [16] [17] Therefore, it is likely that pharmacogenetic variations affecting drug exposure may determine betweenpatient variability in susceptibility toward EFV-based highly active ART (HAART)-induced liver injury.
Although EFV-containing HAART is the preferred regimen in resource-limited settings, data on incidence and predictors of EFV-based ART from African HIV patients are limited. 4, [18] [19] [20] [21] Incidence of DILI varies between population, so do the predictors because of variation in the genetic profile of participants and other associated factors. Although defining DILI and identifying risk factors are controversial areas that need further investigation, few studies have been conducted to identify predictors, assess the incidence and severity of HAART-induced liver injury. No study, however, has been done so far in an Ethiopian setting, and studies done elsewhere in Africa are limited and nonconclusive. 4, 22 The majority of HIV/AIDS patients live in sub-Saharan Africa, with B22 million people infected in the region. 23 Ethiopia, the second densely populated country in Africa, has 1.32 million HIV-infected individuals, 24 and with the advent of ART, mortality and morbidity have significantly reduced. However, the associated complications have seriously compromised the expected success rate in HIV patients because of drug toxicities, drug interactions, development of resistance and poor adherence to therapy. 23 To our knowledge, no association studies on pharmacogenetic variations and steady-state EFV kinetics with respect to susceptibility to EFV-based ART-induced liver injury have been reported. We performed a comprehensive prospective study to assess the incidence, timing and to evaluate EFV plasma concentrations and pharmacogenetic factors as potential predictors for the development of EFV-based ART-induced liver injury. Possible effect of sex, demographic, pretreatment clinical and biochemical variables, EFV kinetics and common genetic variants of CYP2B6, CYP3A5, UGT2B7 and ABCB1 as predictors of EFV-based HAART-induced liver injury was investigated. The results indicate a higher incidence of EFV-based ART-induced liver injury in Ethiopian HIV patients, and apart from elevated liver enzyme level, CYP2B6 genetic variations and high EFV plasma level as its predictors.
Materials and methods

Study participants
In this prospective cohort study, which was conducted from June 2007 to June 2010, we enrolled all consecutive antiretroviral-naïve HIV-positive individuals who came to the three study sites: Kazanchis and Beletshachew Health Centers, and Black Lion Specialized Referral and Teaching University Hospital in Addis Ababa, Ethiopia. A total of 285 participants participated in the study. The eligibility criteria were age X18 years, CD4 count o200 cells ml À1 and not pregnant. None of the participants received isoniazid prophylaxis and treatment for tuberculosis 2 years before enrolment and during the study period. Study participants were screened to ensure that they had no comorbidity (such as tuberculosis) requiring administration of drugs that would be likely to interact with EFV. The study protocol was approved by Ethics Review Committees of Addis Ababa University, Ethiopian Science and Technology Ministry and Karolinska Institutet, Sweden. Prior written informed consent was obtained from all the participants.
Treatment and laboratory analysis EFV-based HAART was initiated with stavudine/lamivudine/ EFV (D4T/3TC/EFV) or zidovudine/lamivudine/EFV (AZT/ 3TC/EFV) or tenofovir/lamivudine/EFV (TDF/3TC/EFV). A complete medical history and physical examination were taken from each participant before enrolment and whenever they came for scheduled and unscheduled visits. Laboratory tests performed before antiretroviral initiation included complete and differential blood counts, platelet count, CD4 count, HIV RNA determination, hepatitis B surface antigen, anti-hepatitis C antibody, serum albumin, renal function tests, liver function tests including, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase and direct and total bilirubin. Follow-up liver function tests were performed at the 1st, 2nd, 4th, 8th, 12th, 24th and 48th weeks after initiation of ART.
CYP2B6, CYP3A5, UGT2B7 and ABCB1 genotyping Blood sample was obtained from 251 patients for genotype analysis. Genomic DNA was isolated from peripheral blood leukocytes using QIAamp DNA Maxi Kit (QIAGEN GmbH, Hilden, Germany). Allelic discrimination reactions were performed using TaqMan (Applied Biosystems, Foster City, CA, USA) genotyping assays: (C__7586657_20 for ABCB1 3435C4T, C__7817765_60 for CYP2B6 516G4T (CYP2B6*6), C__30720663_20 for UGT2B7-372G4A (UGT2B7*2b,*2c,*2d and *2f), C__26201809_30 for CYP3A5 6986A4G (CYP3A5*3), C__30203950_10 for CYP3A5 14690G4A (CYP3A5*6)) and C__32287188_10 for CYP3A5g.27131_27132insT (CYP3A5*7) on ABI 7500 FAST (Applied Biosystems). The final volume for each reaction was 10 ml, consisting of 2 Â TaqMan Universal PCR Master Mix (Applied Biosystems), 20 Â drug metabolizing genotype assay mix (Applied Biosystems) and 10 ng genomic DNA. The PCR profile consisted of an initial step at 50 1C for 2 min and 50 cycles at 95 1C for 10 min and 92 1C for 15 s. Genotyping was carried out at the Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital, Huddinge, Stockholm, Sweden.
Quantification of plasma EFV and 8-hydroxyefavirenz concentration
On the fourth week of EFV-based HAART, 8-ml blood samples were collected 16 h after EFV dosing in a Vacutainer CPT (Becton Dickinson, Heidelberg, Germany) from 212 patients, centrifuged (1700 g for 20 min) and a 2-ml plasma aliquot was taken and stored at À80 1C for determination of EFV and its metabolite concentration. Plasma samples were sent in dry ice to the Department of Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Germany. The determination of plasma EFV and 8-hydroxyefavirenz concentration by liquid chromatography-mass spectrometry was performed as described previously. 25 The lower limits of quantification in plasma were 10.0 ng ml À1 for EFV and 0.4 ng ml À1 for 8-hydroxyefavirenz. The EFV (8-hydroxyefavirenz) calibration range was 10-10 000 ng ml À1 (0.4-400 ng ml À1 ). Linear regression with 1/x weighing resulted in correlation coefficients of r 2 40.99. Accuracy and precision (within batch and batch to batch) of the assay fulfilled all recommendations of the Food and Drug Administration guidelines.
Case identification
Patients with DILI were identified according to the CIOMS (Council for International Organizations of Medical Science) criteria, which are based on selected laboratory liver parameters (CIOMS laboratory criteria and the exclusion of any disease-related causes of liver injury). 26 
Statistical analysis
Baseline demographic and laboratory parameters were presented as median and interquartile range for continuous variables and as percentages for categorical variables. Univariate and multivariate Cox proportional hazards models were used to check for the potential predictors of DILI, and Kaplan-Meier curves were drawn to estimate the incidence of DILI over time. Plasma EFV, 8-hydroxyefavirenz levels and EFV/8-hydroxyefavirenz metabolic ratio (MR) were log10 transformed to normalize their distribution for statistical analysis. The log distributions were then confirmed to be normally distributed by the Kolmogorov-Smirnov test and Shapiro-Wilk W test. Independent t-test was used to analyze the association of log-transformed plasma EFV, 8-hydroxyefavirenz and EFV/8-hydroxyefavirenz ratio with DILI. Incidence of DILI was calculated as the number of episodes per 100 persons exposed per year. Variables with Po0.05 were considered potential predictors for DILI. IBM, SPSS version 19.0 (SPSS, Chicago, IL, USA) for complete data analysis and Statistica version 10 (StatSoft Inc., Tulsa, OK, USA) for graphical data presentation were employed.
Results
Characteristics of study participants A total of 285 antiretroviral treatment-naïve HIV-positive patients with a CD4 count of p200 cells were prospectively enrolled into the study. Twenty-four patients had X2 times the upper normal limit of AST and/or ALT before initiation of ART; hence, they were excluded from the statistical analysis. The remaining 261 patients received EFV-based ART, out of whom 138 (52.9%), 113 (43.3%) and 10 (3.8%) received D4T/3TC/EFV, AZT/3TC/EFV and TDF/3TC/EFV, respectively. Majority of the study participants were women (n ¼ 186, 71.3%). The median age of participants was 34 years (interquartile range, 28-40 years). The prevalence of positive hepatitis B surface antigen and hepatitis C virus antibody was 15 (5.7%) and 7 (2.7%), respectively; 3 (1.1%) were positive for both hepatitis B and C. Sociodemographic and baseline clinical and laboratory characteristics of study participants are presented in Table 1 .
EFV-based HAART-induced liver injury
Twenty-four patients (8.4%) had pretreatment liver toxicity (AST/ALT42 Â upper normal limit: 50 Ul À1 was used as an upper normal limit), and therefore were excluded from the association analysis. Among the 261 patients who had normal baseline liver test, a total of 41 (15.7%) patients developed DILI after initiation of EFV-based HAART, and the incidence rate was 27.9 per 100 person-years. The median time for the development of DILI and severe DILI was 2 (interquartile range, 1-8 weeks) and 4 weeks after HAART initiation, respectively (interquartile range, 1-8 weeks). The majority (37, 90.2%) of them developed DILI within the first 8 weeks of therapy. Association of different clinical and laboratory markers, including genotype and plasma EFV level, with the development of DILI is presented in Tables 2  and 3 . Pattern of change in liver enzyme levels over time was different between those who developed DILI and those who did not. The change in AST/ALT levels in DILI cases was expressed as an initial increase, followed by a gradual decrease, whereas a continuous decline with time was observed in non-DILI controls. Only nine patients (3.4% or 6.13 per 100 person-years) had severe DILI. Hyperbilirubinemia was seen in three (1.1% or 2.04 per 100 personyears) patients, out of whom two had elevated liver enzymes (X2 times the upper normal limit). Of the 41 participants who developed DILI with ART, 4 died during the follow-up period and none of the deaths were attributed to liver failure, as they did not have severe DILI. Only 2 out of the 11 patients with severe DILI had to change their antiretroviral drugs, because of peripheral neuropathy.
CYP2B6, CYP3A5 and ABCB1 genotype
Genotype distribution between cases and controls and their association with DILI using multivariate Cox regression analysis considering time to event is presented in Table 3 . The overall allele frequency of CYP2B6*6, CYP3A5*3, CYP3A5*6, CYP3A5*7, ABCB1 3435C4T and UGT2B7-372G4A was 31.0%, 63.7%, 12.9%, 0%, 22.0% and 48.0%, respectively. Haplotype analyses indicate no linkage between CYP3A5 single-nucleotide polymorphisms. Therefore, subjects were grouped on the basis of number of functional CYP3A5 allele (CYP3A5*1) for statistical analysis. The frequency of patients with two, one and zero functional CYP3A5*1 alleles was 6%, 35% and 59%, respectively. There was no significant difference between the observed and expected genotype frequency according to the HardyWeinberg law.
Potential predictors for EFV-based HAART-induced liver injury
Independent t-test analysis showed significant differences in baseline AST (95% confidence interval (CI) ¼ 1.01-1.05; P: 0.01), ALT (95% CI ¼ 1.01-1.06; P: 0.035), alkaline phosphatase (95% CI ¼ 1.00-1.01; P: 0.016) and steady-state plasma EFV levels (95% CI ¼ 1.31-14.55; P: 0.017) between DILI cases and controls were much higher in cases than in controls. Comparison of plasma EFV, 8-hydroxyefavirenz and EFV/8-hydroxyefavirenz ratio between DILI cases and controls is presented in Figure 2 . Patients with lower baseline platelet (95% CI ¼ 56.21-16.14; P: 0.03), and albumin (95% CI ¼ 0.29-0.96; P: 037), were also at a higher risk for development of DILI. We performed multivariate Cox regression analysis, including all baseline biochemical variables, demographic, sex, pharmacogenetic variation and EFV plasma level (Tables 2 and 3 ). The result indicated elevated pretreatment liver enzymes and plasma EFV concentration as significant predictors of DILI. Furthermore, lower albumin and CD4 count, and CYP2B6 genotype showed a significant association with EFV-based HAART-induced liver injury. There was a tendency for association of lower hemoglobin, body mass index and hepatitis C infection with DILI. Compared with homozygous wild-type genotype, patients with CYP2B6*6/ *6 genotype had significant risk to develop DILI. Cumulative proportion of patients who developed EFV-based HAARTinduced liver injury over time stratified by CYP2B6 genotype is presented in Figure 2 . The relative risk to develop DILI for patients with CYP2B6*6/*6 genotype compared with homozygous wild-type (*1/*1) was 2.7 (95% CI of relative risk ¼ 1.057-6.91, odds ratio ¼ 3.31, 95% CI of odds ratio ¼ 1.01-10.94). In this study, however, sex, age, difference in CYP3A5, UGT2B7 or ABCB1 3435C/T genotype and positive results for both hepatitis viruses did not show significant association with DILI, (Tables 2 and 3) .
Discussion
We performed a comprehensive prospective case-control association study to assess the timing, incidence and to evaluate EFV pharmacokinetic and pharmacogenetic factors as potential predictors for the development of EFV-based HAART-induced liver injury in HIV patients. Demographic, pretreatment biochemical variables, pharmacogenetic variations, plasma EFV and its metabolite concentration as possible biomarkers or predictors of DILI were evaluated using Cox regression considering the time to event. The study identified previously reported and novel predictors that should be considered for the management of DILI. Besides baseline elevation of serum aminotransferase, CYP2B6*6, high plasma EFV level and baseline HIV viral load, lower baseline platelet count, CD4 count and albumin were found to be significant predictors for EFV-based HAART-induced liver injury. To the best of our knowledge, this is the first study to report CYP2B6*6, high plasma EFV level, lower baseline platelet count and albumin as predictors of EFV-based HAART-associated liver injury. The incidence of EFV-based HAART-induced liver injury from our study was relatively higher when compared with that of the previous studies done elsewhere, 4, 21, 22, 27, 28 implying that it is a major concern among HIV patients in Ethiopia. Consequently, this may have a profound effect on adherence, hence the high success rate of HAART in the country. However, the incidence rate of severe DILI, that is, 45 times above the upper normal limit, in our study was 3.4% or 6.13 per 100 person-years, which is similar to the other studies. 4, 9, 27, 29, 30 Unlike a previous study that reported only 50% of EFV-associated liver injury episodes to occur during the first 12 weeks of therapy; 8 in our study, 90.2% of the patients who developed DILI had their episode within the first 8 weeks of therapy. Moreover, all nine patients who had severe DILI developed the episode within the first 8 weeks. Thus, for those patients with underling and predisposing risk factors, it is advisable to perform frequent monitoring of serum aminotransferase level during the first 8 weeks, for early detection and management of DILI.
Owing to the polymorphic expression and the presence of common defective variant alleles with wide interethnic variations in their distribution, CYP2B6 may be the most important genetic contributor to interindividual and interracial differences in EFV disposition and associated adverse events. 10, 12, [14] [15] [16] [17] Interestingly, we found significant association of CYP2B6*6/*6 genotype with DILI ( Figure 1 ). Association of this variant allele with high EFV plasma level and central nervous system toxicity during early initiation of therapy is described previously. [31] [32] [33] The percentage of patients homozygous for CYP2B6*6 variant allele was more than twofold in cases compared with controls (Table 3) . Furthermore, significant association of DILI with higher plasma EFV level and metabolic ratio but not with its major metabolite, 8-hydroxyefvairenz, was noted ( Figure 2) . Accordingly, a previous study using population pharmacokinetic modeling indicated that high EFV plasma levels, but not nevirapine, is associated with elevated liver enzyme values during the first 6 weeks of treatment. 34 The mechanism for antiretroviral drug-induced liver injury remains elusive and is beyond the scope of the present study. Our finding indicates high EFV level as a possible intermediate biomarker for the association of CYP2B6 genotype as a risk factor for DILI. The high EFV Figure 1 Kaplan-Meier curves to estimate cumulative hazard for the development of efavirenz-based highly active antiretroviral therapyinduced liver injury between the different CYP2B6 genotype groups during 1-year follow-up period. ) and EFV/8-hydroxyefavirenz metabolic ratio (MR) between patients who developed EFV-based highly active antiretroviral therapy-induced liver injury (Yes) and those who did not (No) using independent t-test. Boxes indicate mean±s.e. of the mean; bars indicate mean±1.96 Â s.e. of the mean.
plasma level in patients who developed DILI might be the result of impaired EFV metabolism due to liver injury caused by other factors. However, the association of DILI with CYP2B6*6, a variant allele well known to cause increased plasma EFV level, 12, 35 indicates involvement of direct toxicity by EFV and not by its metabolite as a possible mechanism for EFV-based HAART-induced liver injury in HIV patients. In line with this, a recent in vitro study in human hepatic cells using clinically relevant concentration reported that EFV directly affected mitochondrial function in a concentration-dependent manner, inducing a decrease in mitochondrial membrane potential and an increase in mitochondrial superoxide production, followed by a reduction in cellular glutathione content. 36 Although effective, there is a growing concern about EFVrelated adverse events. Cases of acute liver failure associated with EFV-based HAART requiring liver transplantation are reported. 37, 38 EFV displays wide interindividual variability in its kinetics and dynamics, thus, the need for individualized dosing and therapeutic drug monitoring to reduce the associated adverse events such as DILI and central nervous system toxicity during early therapy. Therapeutic drug monitoring, however, is not routinely performed in resource-constrained African countries such as Ethiopia. Genotyping practice in HIV clinics could be another option to identify individuals who are at a risk of having adverse events due to high EFV plasma concentration. Recently, the combined use of therapeutic drug monitoring with pharmacogenetic testing is advocated to optimize EFV therapy. 39 In our cohort, prognosis of patients who developed DILI was good. Even if four patients died, none was attributed to liver failure. Thus, DILI is not a major cause of death but rather a cause for non-adherence. 5, 40 To apply our findings to other settings, however, limitations need to be recognized. Notably, our study cohort consisted of predominantly female, younger age and sick people, and the frequency of hepatitis B and hepatitis C was low. Consequently, we may have underestimated the effect of sex, age, body mass index, hepatitis B and C on EFV-based HAART-related liver injury. However, the sociodemographic characteristics of our study population are representative of the situation in Ethiopia and possibly other African countries where most HIVinfected groups are younger in age and female. EFV-metabolizing enzymes are highly polymorphic in black populations. Africans are the most divergent population with respect to pharmacogenetic variations compared with white and Asian populations. 41 Previously, we reported a finding of high CYP3A4/3A5 enzyme activity and unique distribution of CYP3A5 and CYP2D6 variant alleles in Ethiopians compared with other populations. 42, 43 Hence, finding from one population may not be directly extrapolated to other population in Africa. Furthermore, incidence and risk factors for DILI vary between populations and depending on the type of the ART used. It is our understanding that further case-control association studies are yet required to elucidate the combined effect of genetic and biological factors on EFV-induced adverse events.
In summary, the incidence of EFV-based ART-associated liver injury was relatively higher among the Ethiopian cohort. CYP2B6*6 is a possible genetic marker, whereas high plasma EFV level is the intermediate biomarker for EFVassociated liver injury in Ethiopian HIV patients. CYP2B6 genotyping of HIV patients in clinical practice needs to be encouraged not only to identify patients at risk of EFVinduced central nervous system toxicity but also to identify patients who are at risk of developing DILI. Close follow-up and regular monitoring of plasma EFV concentration and liver enzymes during early therapy is recommended, particularly in patients with the described underlying risk factors for early diagnosis and management of EFV-based HAART-induced liver injury.
